^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Malignant Pleural Mesothelioma
    Drug:cisplatin (DNA synthesis inhibitor) +
    pemetrexed (Thymidylate synthase inhibitor, THF dehydrogenase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Published date:
    05/26/2022
    Excerpt:
    Pemetrexed Injection is a folate analog metabolic inhibitor indicated...initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Published date:
    07/28/2015
    Excerpt:
    Recommendation 4...The first- and second-line treatment of unresectable mesothelioma...Anti-folate/platinum doublet is the only approved standard of care...Combination doublet chemotherapy of cisplatin, with either pemetrexed or raltitrexed, has shown a longer survival compared with cisplatin alone…
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Excerpt:
    …the NCCN Panel recommends cisplatin/pemetrexed (category 1) for patients with MPM.
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ScienceDirect
    Title:

    Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program

    Published date:
    01/07/2008
    Excerpt:
    The pemetrexed plus cisplatin group demonstrated a response rate of 26.3% compared with 21.7% for the pemetrexed plus carboplatin group, with similar 1-year survival rates (63.1% versus 64.0%) and median time to progressive disease (7 months versus 6.9 months)....This large EAP confirmed the activity of pemetrexed plus cisplatin and pemetrexed plus carboplatin in chemonaïve patients with MPM, demonstrating clinically similar time to progressive disease and 1-year survival rates.
    DOI:
    10.1097/JTO.0b013e31817c73d6